Predict your next investment

HEALTHCARE

See what CB Insights has to offer

Stage

Other Investors | Dead

About EpiCare

EpiCare sells products that heal wounds and burns, and minimize scar tissue. All of EpiCare's products are Generally Regarded as Safe (GRAS) by the FDA and can be sold without a prescription. These products heal damaged skin faster because they accelerate the body's natural microcirculation by bringing blood faster to the affected area. Unlike the current potent drugs used for wound and burn purposes, EpiCare's products have no side effects, are non-antibiotic, and are based on Arginine Aminobenzoate—a naturally derived active ingredient.EpiCare's diabetic foot ulcer cream has been proven to perform better than Silvadene, the current leading product for this use. For kitchen burns, the ChefAid product is currently being sold through Ecolab and Sur La Table. For horse and swine wounds, EpiCare's products are marketed by Alpharma. EpiCare is also in development tests with Monsanto for a product for mastitis, which is a major problem with dairy cattle.

EpiCare Headquarter Location

66 Madison Avenue

New York, New York, 10016,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EpiCare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiCare is included in 2 Expert Collections, including Pharma Supply Chain.

P

Pharma Supply Chain

1,258 items

D

Diabetes

1,750 items

EpiCare Patents

EpiCare has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/13/2015

5/31/2016

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/13/2015

00/00/0000

Grant Date

5/31/2016

00/00/0000

Title

Subscribe to see more

Related Topics

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.